-
血管生成是从原有血管芽生出新生毛细血管的过程, 其中生理性血管生成在维持正常的脉管系统、女性生殖周期及促进创伤愈合方面起着重要的作用, 而病理性血管生成则与糖尿病视网膜病变、关节炎、子宫内膜异位症、恶性肿瘤生长及转移等密切相关[1]。研究证实, 肿瘤大于2 mm时, 主要通过新生血管输送足够的养分和排除代谢废物, 并为其转移提供便利[2]; 血管生成需多种因子的参与, 其中血管内皮生长因子(vascular endothelial growth factor, VEGF)信号通路是主要的限速环节[3]; VEGF受体(VEGF receptor, VEGFR)在肿瘤血管内皮细胞及多种肿瘤细胞膜上呈高水平表达, 是具有潜在应用价值的靶分子, 并已成为靶向抗肿瘤血管生成治疗的研究热点。受体显像是集配体-受体结合的高特异性和放射性核素探测的高敏感性于一体的分子影像诊断技术, 能够准确显示体内受体的空间分布、密度与亲和力, 在临床肿瘤诊疗中已展示出广阔的应用前景。本文就VEGF、VEGFR、VEGFR与肿瘤及肿瘤VEGFR显像研究现状进行简要综述。
肿瘤血管内皮生长因子受体核素显像研究现状
Review present study on vascular endothelial growth factor receptor imaging
-
摘要: 肿瘤血管生成是肿瘤生长与转移生物学行为的重要基础。血管内皮生长因子(VEGF)及其受体(VEGFR)在肿瘤血管生成过程中起到了关键性的作用。VEGFR已成为目前肿瘤血管生成的诊断和治疗研究领域具有潜在应用价值的分子靶点。放射性核素受体显像具有灵敏度高、特异性强的优点,能够客观、准确显示体内肿瘤组织VEGFR的分布、密度及与其配体的结合亲和力,有助于肿瘤的诊断与鉴别诊断、临床分期、复发与转移的探测,并对临床实施针对VEGFR的肿瘤生物治疗具有积极的指导作用。
-
关键词:
- 血管内皮生长因子 /
- 受体, 血管内皮生长因子 /
- 肿瘤 /
- 放射性核素显像
Abstract: Tumor angiogenesis is the foundation of tumor growth and metastasis.The vascular endothelial growth factor(VEGF)and VEGF receptor(VEGFR)plays a pivotal role in regulating tumor angiogenesis.VEGFR has become a common molecular target which has a potential value in angiogenesis diagnosis and therapy at present.Radionuclide receptor imaging has the advantage of high sensitivity and specificity, by which distribution density of VEGFR and its affinity with its ligand in tumor tissue can be revealed.VEGFR imaging is helpful in diagnosis, staging and detection of recurrence and metastasis of tumor and plays an instructive role in biological therapy of tumor mediated by VEGFR. -
[1] Gasparini G, Longo R, Toi M, et al. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol, 2005, 2(11): 562-577. doi: 10.1038/ncponc0342 [2] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenicswitch during tumorigenesis. Cell, 1996, 86(3): 353-364. doi: 10.1016/S0092-8674(00)80108-7 [3] Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol, 2009, 29(6): 789-791. doi: 10.1161/ATVBAHA.108.179663 [4] Cho NK, Keyes L, Johnson E, et al. Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell, 2002, 108(6): 865-876. doi: 10.1016/S0092-8674(02)00676-1 [5] Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol, 2001, 280(6): C1367-C1374. doi: 10.1152/ajpcell.2001.280.6.C1367 [6] Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999, 126(13): 3015-3025. doi: 10.1242/dev.126.13.3015 [7] Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase(vascular endothelial growth factor receptor-1)in pathological angiogenesis. Cancer Res, 2001, 61(3): 1207-1213. [8] Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutess hematopoiesis by recruiting VEGFR1(+)stem cells from bone-marrowmicroenvironment. Nat Med, 2002, 8(8): 841-849. doi: 10.1038/nm740 [9] Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem, 1994, 269(43): 26988-26995. doi: 10.1016/S0021-9258(18)47116-5 [10] Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 1995, 376(6535): 62-66. doi: 10.1038/376062a0 [11] Zhao Q, Egashira K, Hiasa K, et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol, 2004, 24(2): 2284-2289. [12] Tanigawa N, Amaya H, M atsumura M, et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 1997, 15(2): 826-832. doi: 10.1200/JCO.1997.15.2.826 [13] 宋述梅, 曾莉, 吴健, 等. VEGF受体KDR胞外Ⅴ-Ⅶ区的克隆、单抗制备及KDR在不同来源肿瘤组织中的表达. 中华肿瘤杂志, 1999, 21(2): 96-98. doi: 10.3760/j.issn:0253-3766.1999.02.004
[14] Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer, 2001, 91(6): 789-796. doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.0.CO;2-K [15] Cornelissen B, Oltenfreiter R, Kersemans V, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol, 2005, 32(5): 431-436. doi: 10.1016/j.nucmedbio.2005.03.005 [16] Yoshimoto M, Kinuya S, Kawashima A, et al. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. Nucl Med Biol, 2006, 33(8): 963-969. doi: 10.1016/j.nucmedbio.2006.08.006 [17] Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled(99m)Tc-HYNICVEGF. Eur J Nucl Med Mol Imaging. 2006, 33(7): 841-848. doi: 10.1007/s00259-006-0099-1 [18] Qin ZX, Li QW, Liu GY, et al. Imaging targeted at tumor with (188)Re-labeled VEGF (189)exon 6-encoded peptide and effects of the transfecting truncated KDR gene in tumor-bearing nude mice. Nucl Med Biol, 2009, 36(5): 535-543. doi: 10.1016/j.nucmedbio.2009.02.001 [19] Chan C, Sandhu J, Guha A, et al. A human transferrin-vascular endothelial growth factor(hnTf-VEGF)fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. J Nucl Med, 2005, 46(10): 1745-1752. [20] Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med, 2007, 13(4): 504-509. doi: 10.1038/nm1522 [21] Schenone S, Bondavalli F, Botta M. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem, 2007, 14(23): 2495-2516. doi: 10.2174/092986707782023622 [22] Hetian L, Ping A, Shumei S, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem, 2002, 277(45): 43137-43142. doi: 10.1074/jbc.M203103200 [23] Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst, 2002, 94(19): 1484-1493. doi: 10.1093/jnci/94.19.1484 [24] Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med, 2007, 48(8): 1313-1319. doi: 10.2967/jnumed.107.041301 [25] Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med, 2006, 47(12): 2048-2056. [26] Wang H, Cai W, Chen K, et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging, 2007, 34(12): 2001-2010. doi: 10.1007/s00259-007-0524-0
计量
- 文章访问数: 1762
- HTML全文浏览量: 643
- PDF下载量: 4